Catalent to acquire gene therapy service firm Paragon

Catalent Inc said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion, helping the drug developer expand its capabilities to make specialized and costly treatments.

Catalent to acquire gene therapy service firm Paragon

The $1.2 billion deal is the latest designed to support the flood of gene therapies in development

Mon 15 Apr 19 from CandEN

Catalent seeks slice of gene therapy market with Paragon buy

Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech ...

Mon 15 Apr 19 from Reuters

Catalent pushes into gene therapy with $1.2 billion buyout of Paragon Bioservices

Catalent Inc said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion, helping the drug developer expand its capabilities ...

Mon 15 Apr 19 from Reuters

Catalent to buy Paragon Bioservices for $1.2 billion: WSJ

Drug developer Catalent Inc has agreed to buy privately held Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

Sun 14 Apr 19 from Reuters

  • Pages: 1

Bookmark

Bookmark and Share